A Therapeutic Update on the Management of Patients with Metastatic Renal Cell Carcinoma
This webcast on metastatic renal cell carcinoma (mRCC) is based on a roundtable discussion among three key opinion leaders in the field. The experts will present updates on the management of mRCC and summarize and discuss the latest clinical trial data presented during the ESMO 2017 Congress, held in Madrid, Spain, on September 8–12, 2017. Advances in the use of targeted therapies such as VEGFR inhibitors, novel immunotherapies, and combination therapies including PD-1/PD-L1 and CTLA4 targeting agents will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with mRCC.
*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis and expert perspectives through conference coverage educational programs.
This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with Metastatic Renal Cell Carcinoma.
Upon completion of this activity, participants will be better able to do the following:
- Assess the molecular profiling of mRCC
- Understand the mode of action of the established targeted therapies VEGF and mTOR inhibitors, and emerging therapies such as checkpoint inhibitors and tumor vaccines
- Analyze clinical trial data on targeted (emerging) therapies for the treatment of mRCC presentd at ESMO 2017
- Apply the above knowledge to develop data-driven, individualized treatment plans to improve treatment selection and sequencing and outcomes for patients with mRCC
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
Consultant/Advisor: AstraZeneca, Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd
Grant/Research Support: Novartis AG, F. Hoffmann-La Roche Ltd
Consultant/Advisor: Bristol-Myers Squibb Company, Exelixis, Inc., Genentech, Inc, Novartis AG, Peloton Therapeutics, Inc., Pfizer Inc.
Grant/Research Support: Bristol-Myers Squibb Company, Exelixis, Inc., Novartis AG, Peloton Therapeutics, Inc., Pfizer Inc.
Consultant/Advisor: AstraZeneca, Bristol-Myers Squibb Company, EUSA Pharma, Inc., Ipsen, Janssen Global Services, LLC, Novartis AG, Peloton Therapeutics, Inc., Pfizer Inc.
Speakers’ Bureau: AstraZeneca, Bristol-Myers Squibb Company, Ipsen, Novartis AG, Peloton Therapeutics, Inc., Pfizer Inc.
Astrid Stoker; Elena Knoche; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Bristol-Myers Squibb Company.
Jointly provided by the Elsevier Office of Continuing Medical Education and Excerpta Medica.
CME CREDIT (PHYSICIANS)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Excerpta Medica. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Excerpta Medica and Bristol-Myers Squibb Company do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions.
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
- All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.
Release date: December 7, 2017
Expiration date: December 6, 2018